Article
Pharmacology & Pharmacy
Li Wang, Xiaolin Li, Bin Zhao, Dan Mei, Jiandong Jiang, Jingli Duan
Summary: Elderly male patients with lung and thymus malignancies are frequently predisposed to TLS. ICI therapies could induce TLS in both solid and hematological malignancies. The rapid onset time and poor outcomes of patients prompt caution from health-care professionals.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Piaohong Chen, Jianwei Li, Huiwen Tan
Summary: Immune checkpoint inhibitors (ICIs) are a novel class of antitumor drugs that enhance T cell activity by blocking immune checkpoints from binding to their ligands. However, ICIs can disrupt T cell immune tolerance to self-antigens, leading to a series of immune-related adverse events (irAEs). Immune checkpoint inhibitor-induced hypophysitis (IH) is a relatively uncommon irAE that is difficult to diagnose accurately due to non-specific clinical manifestations. This article summarizes the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of IH.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Kamonlapat Supimon, Thanich Sangsuwannukul, Jatuporn Sujjitjoon, Thaweesak Chieochansin, Mutita Junking, Pa-thai Yenchitsomanus
Summary: Researchers developed a novel CAR-T cell therapy targeting the overexpressed MUC1 protein on cholangiocarcinoma (CCA) cells. By introducing the PD-1-CD28 switch receptor into CAR-T cells, they were able to activate CD28 signaling and counteract the immune suppression caused by MUC1. The experimental results demonstrated that this new CAR-T cell showed enhanced anti-tumor activity, suggesting its potential for CCA treatment.
Review
Pharmacology & Pharmacy
Ze Xiang, Jiayuan Li, Zhengyu Zhang, Chao Cen, Wei Chen, Bin Jiang, Yiling Meng, Ying Wang, Bjoern Berglund, Guanghua Zhai, Jian Wu
Summary: Immunotherapy with immune checkpoint inhibitor (ICI) drugs is a hot topic in cancer treatment. Our study used Bayesian model to comprehensively evaluate the safety and efficacy of ICI drugs. Different ICI drug therapies may have different risks in terms of progression-free survival (PFS), overall survival (OS) and severe adverse events (AEs). Treatment with cemiplimab was found to be the best choice in terms of PFS and OS. Our study provides new insights and strategies for the clinical practice of ICI drugs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Chunyi Shen, Zhen Zhang, Yonggui Tian, Feng Li, Lingxiao Zhou, Wenyi Jiang, Li Yang, Bin Zhang, Liping Wang, Yi Zhang
Summary: The study demonstrated that combining SFN with CAR-T cells enhanced cytotoxicity and antitumor functions by modulating the PD-1/PD-L1 pathway, suggesting a promising strategy for cancer immunotherapy.
Article
Immunology
Athitaya Luangnara, Salin Kiratikanon, Thanika Ketpueak, Thatthan Suksombooncharoen, Chaiyut Charoentum, Busyamas Chewaskulyong, Napatra Tovanabutra, Siri Chiewchanvit, Surapon Nochaiwong, Mati Chuamanochan
Summary: This study investigated the incidence and associated factors of cutaneous immune-related adverse events (cirAEs) among cancer patients in northern Thailand, and found that the incidence of cirAE-related ICI therapy was comparable to that in white populations. Age over 75 and pre-existing chronic kidney disease stages 3-4 were identified as prognostic risk factors for cirAE-related ICI therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Rita C. Acurcio, Sabina Pozzi, Barbara Carreira, Marta Pojo, Nuria Gomez-Cebrian, Sandra Casimiro, Adelaide Fernandes, Andreia Barateiro, Vitor Farricha, Joaquim Brito, Ana Paula Leandro, Jorge A. R. Salvador, Luis Graca, Leonor Puchades-Carrasco, Luis Costa, Ronit Satchi-Fainaro, Rita C. Guedes, Helena F. Florindo
Summary: This study identifies a new class of small molecule candidates that can regulate the PD-L1/PD-1 signaling pathway, promoting the infiltration of effector CD8 T cells in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Peng Sun, Liwei Zhang, Yulei Gu, Shunbo Wei, Zhiwei Wang, Mingxing Li, Wang Wang, Zhiju Wang, Hualong Bai
Summary: The inhibition of the PD-1 pathway shows promise as a therapeutic strategy for preventing the progression of AAA and pseudoaneurysms. In the experiments, injection of PD-1 antibody and BMS-1 significantly inhibited AAA progression, and they were successfully conjugated to decellularized rat thoracic artery patches to inhibit the progression of pseudoaneurysms as well.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Immunology
Rongping Chen, Lixin Zhou
Summary: Sepsis, one of the leading causes of death in ICU patients, has shown promising treatment potential with anti-PD-1/PD-L1 antibodies due to the important role of the PD-1 signaling pathway in the disease. The relationship between the PD-1 signaling pathway and immune cells as well as organ dysfunction in sepsis has been widely studied, emphasizing the potential application of the PD-1 signaling pathway in sepsis treatment.
CLINICAL IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Andrzej Kowalski, Katarzyna Malinowska, Jurek Olszewski, Hanna Zielinska-Blizniewska
Summary: The interaction of PD-1 and PD-L1 in laryngeal tumors allows cancer cells to escape from the immune system. Gene expression of PD-1 and PD-L1 was significantly higher in tumor tissue compared to unchanged mucosa, with higher expression levels associated with larger tumor sizes. These findings suggest potential for targeted immunotherapy with anti-PD1 and anti-PD-L1 monoclonal antibodies in treating laryngeal tumors.
Review
Oncology
David Johnson, Brigette B. Y. Ma
Summary: The upregulation of the PD-1/PD-L1 pathway is a possible immune-evasion mechanism in Epstein-Barr virus-associated nasopharyngeal cancer (NPC). Therapeutic targeting of this pathway is actively researched in NPC, with multiple monoclonal antibodies currently under evaluation in clinical settings. Combinatorial strategies involving cytotoxic chemotherapy, radiotherapy, and other immunotherapeutic agents are also being explored in clinical trials for NPC.
Article
Biochemistry & Molecular Biology
Kaitang Huang, Meiling Hu, Jiayun Chen, Jinfen Wei, Jingxin Qin, Shudai Lin, Hongli Du
Summary: This study analyzed the heterogeneity within tumor immune microenvironment (TIME) subtypes and found associations with prognosis, immune cell composition, genomics, and transcriptomics patterns. The combination of TIL Z score and PD-L1 expression was shown to be a robust method for classifying TIME and predicting response to ICI therapy. The findings provide insight for screening benefited groups in ICI immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Akio Onishi, Shigeo Fuji, Shigehisa Kitano, Akiko Miyagi Maeshima, Kinuko Tajima, Junko Yamaguchi, Ichiro Kawashima, Akihisa Kawajiri, Tomonari Takemura, Ayumu Ito, Takashi Tanaka, Keiji Okinaka, Yoshihiro Inamoto, Saiko Kurosawa, Sung-Won Kim, Wataru Munakata, Dai Maruyama, Kensei Tobinai, Takahiro Fukuda
Summary: This study aims to identify the association between the expression profile of immune checkpoint proteins on ATLL cells and clinical outcomes. The analysis shows that CTLA-4, PD-1, and PD-L1 expressions were adverse prognostic factors in patients with aggressive ATLL.
ANNALS OF HEMATOLOGY
(2022)
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
